



ADAP Advocacy  
PO Box 846  
Nags Head, NC 27959

[adapadvocacy.org](http://adapadvocacy.org)

**Board of Directors:**

**Chair**  
Jen Laws  
Slidell, LA

**Secretary**  
Guy Anthony  
Brooklyn, NY

**Treasurer**  
Wanda Brendle-Moss, R.N.  
Winston-Salem, NC

Erin Darling, Esq.  
Washington, DC

Robert "Bobby" Dorsey, Esq.  
Washington, DC

Eric Flowers  
Oakland, CA

Lyne Fortin, B.Pharm, MBA  
Montreal, Canada

Hilary M. Hansen  
Washington, DC

Lisa Johnson-Lett  
Birmingham, AL

Theresa Nowlin  
Dorchester, MA

Shabbir Imber Safdar  
San Francisco, CA

Jennifer Vaughan  
Watsonville, CA

Marcus A. Wilson  
Orlando, FL

**CEO**  
Brandon M. Macsata  
Washington, D.C.

**Directors Emeritus:**  
Michelle Anderson  
William Arnold – *in memoriam*  
John D. Kemp, Esq.  
Gary Rose – *in memoriam*  
Joyce Turner Keller  
Rani Whitfield, M.D.

## ADAP Advocacy Publishes Final Report for Patient Perspectives on Long-Acting Injectables

### *Comprehensive Report Offers Patient Access Considerations for Injectable HIV Therapies & Injectable HIV Pre-Exposure Prophylaxis*

For Immediate Release:

June 27, 2024

Media Contact:

[info@adapadvocacy.org](mailto:info@adapadvocacy.org)

WASHINGTON, D.C. – ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, published its final report and executive summary on patient perspectives from people living with HIV about approved LAIs medications for the treatment of HIV/AIDS, as well as their HIV-negative counterparts about HIV Pre-Exposure Prophylaxis (PrEP) injectables. The findings yield valuable insights to the barriers being faced by both populations.

LAIs are prescription medications designed to either prevent the transmission of HIV or treat HIV over an extended period. These medications can be used to replace daily oral medications. However, anecdotal evidence suggests that access barriers remain.

**Brandon M. Macsata, CEO of ADAP Advocacy summarized:** "Over the last few years we've witnessed some amazing policy work being done on long-acting injectables, but often times it lacked the patient-to-patient perspective. ADAP Advocacy's Long-Acting Injectables Project starts to fill that gap and the final report being issued today reflects our commitment to addressing the attitudinal, operational, and other associated barriers patients perceive as preventing them from accessing these life-changing products for both the treatment of HIV, as well as the prevention of HIV. The findings from this project serve as a starting point for ADAP Advocacy to conduct additional patient-centric research to learn more about the barriers as well as facilitators faced by patients seeking long-acting injectables. This project's research questions concerned patient treatment preferences, information pathways, utilization, and barriers to access."

The final report and executive summary are available online, here

<https://adapadvocacy.org/LAIsFinalReport2024/>.

ADAP Advocacy's Long-Acting Injectables Project is made possible with support from Gilead Sciences, Merck, and ViiV Healthcare.

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or its Long-Acting Injectables Project, please email [info@adapadvocacy.org](mailto:info@adapadvocacy.org).

####

**About ADAP Advocacy:** ADAP Advocacy's mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.